Jilted by Janssen, Aduro hit by 13% share price drop

3 October 2018

Immuno-oncology company Aduro BioTech (Nasdaq: ADRO) closed 13% down in the stock market on Tuesday following news that Janssen was walking away from cancer collaborations that it had signed up to with the Californian firm.

Aduro alerted the world in a regulatory filing that Johnson & Johnson’s (NYSE: JNJ) was terminating its agreements on developing therapies for lung and prostate cancers.

In 2014, Janssen was granted an exclusive, worldwide license to research, develop, manufacture, use, sell and otherwise exploit products containing Aduro’s ADU-214, ADU-741 and GVAX Prostate for any and all use, rights to which are all now returning to the smaller company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK